wellrank.ai
Spry logo

Spry

First cited by AI Jun 13, 2026
sprydigital.com

Surfaced organically in AI answers about ozempic. Not yet profiled.

AI Visibility

Visibility trend

Ozempic, daily share of AI answers mentioning Spry, through Jun 13, 2026.

8.3%

Avg position when mentioned: 6.0

By engine

Where Spry is strong, and where it is invisible.

  • Perplexity
    33.3%

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 0 positive mentions
  • 1 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Spry

PerplexityJun 13, 2026, 11:11 UTC
Which online Ozempic providers handle prior authorization with insurance?

Based on current information, several online telehealth providers offer Ozempic prescriptions and assist with the prior authorization (PA) process with insurance companies. However, it is important to note that Ozempic is FDA-approved only for Type 2 Diabetes, not for weight loss, which significantly impacts insurance coverage eligibility. Here are the key online providers that handle prior authorization: PlushCare PA Handling: PlushCare states that their physicians and care team will reach out to your insurer on your behalf to handle the prior authorization request. Note: They emphasize that a Type 2 Diabetes diagnosis is required for insurance approval. The process can take several business days. Cost: They offer virtual visits with insurance (often $30 or less for in-network) or cash pay ($129 for initial visits). Ro (Ro Body) PA Handling: Ro offers an insurance concierge service. Their concierge "fights for coverage," submits all paperwork, and works with the insurance provider to determine coverage for GLP-1 medications. Note: Ro explicitly states Ozempic is not FDA-approved for weight loss. They may prescribe it off-label. Their insurance concierge is separate from the Ro Body membership fee (which is cash-only). Limitation: They currently cannot coordinate coverage for GLP-1s for government insurance plans (e.g., Medicare), though they may assist with private plans. Plastic & Ro (General Telehealth) Many other telehealth platforms (like Ro, PlushCare, Klarity, and HelloKlarity) can* initiate the prescription, but their ability to secure insurance coverage depends entirely on the patient meeting the PA criteria (Type 2 Diabetes). Klarity Health / HelloKlarity: These platforms often focus on weight loss. While they can evaluate weight loss needs, they frequently inform patients that insurance coverage for weight loss is unlikely without a diabetes diagnosis, and they may not have a dedicated "concierge" team to fight for PA in the same way Ro does. CoverMyMeds & Spry (Technology Partners, Not Providers) It is worth noting that many providers use third-party platforms like CoverMyMeds or Spry to automate and submit prior authorization requests electronically. These tools streamline the process for providers but are not the direct patient-facing "providers" themselves. Critical Considerations for Prior Authorization: Diagnosis Requirement: Almost all insurance companies will deny prior authorization for Ozempic if the patient only has a weight loss diagnosis. A Type 2 Diabetes diagnosis is typically mandatory for coverage. Weight Loss vs. Diabetes: If you are seeking Ozempic strictly for weight loss, you may face auto-denials from insurance regardless of the provider. You may need to pay the full cash price (approx. $949/month) or use a savings offer (e.g., from NovoCare). Appeals: If a PA is denied, providers like Ro and PlushCare can assist in filing an appeal or initiating a peer-to-peer review with the insurer. Recommendation: If you have Type 2 Diabetes, PlushCare and Ro are the most robust options for handling PA actively. If you are seeking Ozempic only for weight loss, be prepared that most insurance plans will deny coverage regardless of the provider, and you should verify cash prices or savings programs beforehand.

Mentioned in position 6 of 7

Read full answer with sources →

Public AI visibility history

Daily rank of Spry on our buyer intent questions, per category. A dash means the engines did not cite Spry at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
Ozempic#48

TL;DR

Spry (sprydigital.com) is a digital health platform that appears in AI-generated answers about Ozempic and GLP-1 medications, though its full product scope is not yet widely covered in public sources. According to WellRank's index, Spry currently ranks 15th in AI answer visibility for Ozempic-related queries, capturing 8% visibility on the latest measurement day. Its single recorded AI mention carries a neutral tone, suggesting it is surfacing as a factual reference rather than a recommended destination, and it has not yet built the citation depth of more established telehealth peers.

Company Overview

Spry operates in the digital health and telehealth space, with its blog and web presence suggesting a focus on helping patients navigate insurance coverage and prior authorization for prescription medications including GLP-1 drugs. Its founding date, headquarters, and full business model are not publicly disclosed in widely available sources. The platform appears to function partly as a patient information and navigation resource, and the extent of any direct clinical or prescribing services it offers is not clearly established in the public record.

Product Features

  • Patient-facing guidance on Ozempic and GLP-1 insurance coverage
  • Prior authorization navigation resources
  • Educational blog content on prescription medication access
  • Digital tools or workflows for benefits and coverage checks (scope not publicly detailed)

Target Market

Spry appears to target patients in the United States who are seeking access to GLP-1 medications such as Ozempic, particularly those dealing with insurance prior authorization hurdles. It may also serve individuals managing diabetes or obesity who need help understanding their coverage options. Geographic focus and any clinical specialty beyond GLP-1 access are not publicly disclosed.

Buyer Personas

  • A patient newly prescribed Ozempic who needs help understanding whether their insurance plan will cover the medication.
  • Someone managing type 2 diabetes or obesity who has been denied prior authorization and is looking for a clear path to appeal or alternative coverage.
  • A cost-conscious consumer researching how to reduce out-of-pocket expenses for GLP-1 weight-loss drugs.
  • A caregiver or family member researching prescription coverage options on behalf of a relative starting GLP-1 therapy.

Funding & Performance

Funding stage, investor backing, revenue, and valuation are not publicly disclosed.

Recent Developments

Spry has been producing web content focused on the Ozempic and GLP-1 prior authorization process, as reflected in the source sprypt.com blog on Ozempic insurance coverage and authorization. This content is being picked up by AI answer engines, which is how Spry is surfacing in WellRank's index. No major product launches, partnerships, or funding rounds have been widely reported.

Competitive Landscape

In AI answer engines, Spry is most frequently mentioned alongside Ro, PlushCare, NovoCare, Klarity, HelloKlarity, and CoverMyMeds, according to WellRank co-mention data. These are substantially more established brands: Ro and PlushCare are full telehealth prescribing platforms, NovoCare is Novo Nordisk's own patient support program, and CoverMyMeds is a large prior authorization technology company. Spry's 8% AI visibility is modest relative to these co-mentioned peers, and it has not yet established the review volume or brand recognition that would differentiate it clearly in public comparisons.

Spry vs the brands AI recommends alongside it

The real competitive set in Ozempic: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Spry logo
SpryThis brand
#48
8.3%
CoverMyMeds logo
CoverMyMeds

1 shared answers

#44
8.3%
HelloKlarity logo
HelloKlarity

1 shared answers

#47
8.3%
Klarity logo
Klarity

1 shared answers

#14
16.7%
NovoCare logo
NovoCare

1 shared answers

#41
8.3%

Email me when overtakes Spry

One email the day the ranks flip. Nothing else.

User Sentiment

WellRank's corpus records one AI mention of Spry, which carries a neutral tone with no positive or cautious signals detected. This suggests AI engines are citing Spry as an informational source rather than endorsing or critiquing it. Broader consumer review sentiment is not yet established in widely available public sources, and Verywell Health and similar authoritative outlets that appear in the same answer context have not prominently featured Spry in their own editorial coverage.

Pricing

Pricing for any Spry services or tools is not published in widely available sources.

Sources cited around Spry

The sites engines cite in answers mentioning this brand. Win these, win the answer.

Track Spry weekly

One email a week: rank moves, new competitors, and the answers that changed. No noise.

Work at Spry? Get your AI Visibility Audit.

See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.

Spry: AI visibility report | WellRank